Cargando…
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
BACKGROUND: Despite major advances in the management of metastatic colorectal cancer (mCRC) with liver-only involvement, relapse rates are high and reliable prognostic markers are needed. METHODS: To assess the prognostic impact of BRAF and RAS mutations in a large series of liver-resected patients,...
Autores principales: | Schirripa, M, Bergamo, F, Cremolini, C, Casagrande, M, Lonardi, S, Aprile, G, Yang, D, Marmorino, F, Pasquini, G, Sensi, E, Lupi, C, De Maglio, G, Borrelli, N, Pizzolitto, S, Fasola, G, Bertorelle, R, Rugge, M, Fontanini, G, Zagonel, V, Loupakis, F, Falcone, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580391/ https://www.ncbi.nlm.nih.gov/pubmed/25942399 http://dx.doi.org/10.1038/bjc.2015.142 |
Ejemplares similares
-
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2016) -
KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014) -
Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
por: Schirripa, M, et al.
Publicado: (2013) -
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017) -
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
por: Loupakis, F, et al.
Publicado: (2013)